Benefits
Cardiovascular / Lipid Effects
Naringenin reduces hepatic lipogenesis and improves lipid profile in animal models. Modest human evidence. Mechanism: PPAR-alpha activation similar to fibrates.
Insulin Sensitivity / Glycemic Effects
Animal models show improved insulin sensitivity and reduced hepatic glucose production. Human clinical translation modest.
Antioxidant Activity
Direct free radical scavenging plus Nrf2 pathway activation. Component of cardiovascular and longevity supplementation.
Anti-Inflammatory Effects
Reduces inflammatory cytokine production, modulates NF-κB pathway. Modest anti-inflammatory profile.
Hepatitis C Antiviral Research (Preliminary)
Some research shows naringenin reduces hepatitis C virus secretion in vitro. Theoretical antiviral applications; clinical translation pending.
Mechanism of action
PPAR-Alpha Activation
Naringenin activates peroxisome proliferator-activated receptor alpha (PPAR-alpha) — same nuclear receptor target as fibrate drugs (gemfibrozil, fenofibrate). Reduces lipogenesis, increases fatty acid oxidation.
AMPK Activation
Activates AMP-activated protein kinase — improving glucose uptake, fat oxidation, reduced lipogenesis. Same target as metformin and exercise.
NARINGIN VS NARINGENIN DISTINCTION (Grapefruit Drug Interaction)
CRITICAL: NARINGIN (the glycoside form, abundant in grapefruit) is responsible for the famous grapefruit-drug interaction via inhibition of intestinal CYP3A4 and OATP transporters. NARINGENIN (the aglycone metabolite formed by gut bacteria) has DIFFERENT pharmacology and likely doesn't replicate the full grapefruit effect. Supplemental naringenin should not produce grapefruit-juice level drug interactions, but data is limited.
Antioxidant Pathway Activation
Direct radical scavenging plus Nrf2 transcription factor activation upregulating endogenous antioxidant enzymes.
Clinical trials
Multiple animal studies of naringenin for hyperlipidemia and metabolic syndrome.
Animal models predominantly.
Significant improvements in lipid profile, glucose, insulin sensitivity in animals. Human trials limited and lower quality.
Pharmacokinetic studies establishing naringenin oral bioavailability and metabolism.
Healthy adults.
Naringenin oral bioavailability low (~5-15%); rapidly metabolized to glucuronides and sulfates. Plasma concentrations achievable with supplementation may be insufficient for some in vitro mechanisms.
About this ingredient
NARINGENIN (4',5,7-trihydroxyflavanone) is a CITRUS FLAVANONE — found primarily in GRAPEFRUIT (highest concentration), oranges, lemons, tangerines, and TOMATOES (skin). Distinguished from naringin (its glycoside form abundant in grapefruit) — naringin is converted to naringenin by gut bacteria. Together with hesperidin, naringenin is a major citrus polyphenol.
CRITICAL EVIDENCE-BASED CONTEXT: most preclinical research is on NARINGENIN (the aglycone), but most dietary intake is as NARINGIN (the glycoside). The human relevance is bridged by gut microbiome conversion.
EVIDENCE-BASED USES: (1) Cardiovascular/lipid effects (preclinical strong; human modest); (2) Metabolic syndrome adjunct; (3) Antioxidant; (4) Anti-inflammatory; (5) Hepatitis C antiviral research (preliminary).
CRITICAL CAUTIONS: (1) GRAPEFRUIT-DRUG INTERACTION CLARIFICATION — the famous grapefruit-drug interaction (causing problematic increases in statins, calcium channel blockers, immunosuppressants, certain anticoagulants) is primarily caused by FUROCOUMARINS and BERGAMOTTIN in grapefruit juice, with NARINGIN as secondary contributor; PURE NARINGENIN supplements likely do NOT produce the same magnitude of drug interaction as grapefruit juice; HOWEVER, theoretical concern remains — if on drugs known to interact with grapefruit, discuss with prescriber before naringenin supplementation; SAFER APPROACH: avoid grapefruit-interacting drugs concurrently if possible; (2) BIOAVAILABILITY — oral naringenin bioavailability low (~5-15%); plasma concentrations from supplementation may be insufficient for some in vitro mechanisms; (3) HUMAN CLINICAL DATA LIMITED — most evidence preclinical (cell culture, animal); rigorous human RCTs with naringenin specifically are limited; (4) PREGNANCY/LACTATION — limited safety data at supplemental doses; dietary citrus safe; AVOID concentrated supplementation; (5) HORMONE-SENSITIVE CONDITIONS — theoretical phytoestrogenic effects modest; (6) DOSE — 150-500 mg/day in supplements; standardized dosing not yet well-established; (7) DIETARY INTAKE — grapefruit, oranges, lemons, tomato skins provide naringenin/naringin; can achieve reasonable intake from diet without supplementation; (8) STACKED WITH OTHER POLYPHENOLS — naringenin sometimes combined with quercetin, hesperidin, resveratrol in 'polyphenol' supplements; additive effects theoretical; (9) EMERGING SUPPLEMENT — naringenin is increasingly available as standalone supplement; evidence base is developing; reasonable to expect modest effects similar to other citrus flavonoids; (10) HESPERIDIN COMPARISON — hesperidin (also citrus flavanone) has stronger clinical evidence base (especially for venous insufficiency); naringenin evidence is more preclinical; for general citrus flavonoid benefits, hesperidin or combined products may have stronger justification; (11) The 'grapefruit polyphenols for cholesterol' marketing is mechanistically supported by PPAR-alpha activation but human clinical data is modest at supplement doses; statins and other established lipid drugs remain primary; naringenin is reasonable adjunct or for those preferring natural approach.